Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|April 27, 2018
Treating Chronic Lymphocytic Leukemia in Elderly Patients
Treating Chronic Lymphocytic Leukemia in Elderly Patients
Advertisement
- A 76-year-old male presented with symptoms of low-grade fever, (101.1oF) chills, and weight loss. The patient feels severely fatigued and required extensive rest. He was recently hospitalized for pneumonia.
- PMH: Hypertension controlled on candesartan, diabetes managed with metformin
- PE: Pallor and is weak-appearing, vital signs WNL, enlarged mobile lymph nodes bilaterally (~2.0 cm), anterior cervical chain, no hepatosplenomegaly
- PS, ECOG 2
- Laboratory findings:
- WBC; 18.5 X 109/L, 65% lymphocytes
- Lymphocytes; 86.2 X 109/L
- Hb; 12.2 g/dL
- Platelets; 305 X 109/L
- ANC; 120/mm3
- Flow cytometry; CD5+, CD19+, CD23+, CD38-low,
- Cytogenetics, IgVH mutation status, unknown
- β2M, 2.6 mg/L
- BM biopsy; 50% lymphocytes
- Diagnosis; chronic lymphocytic leukemia
- The patient was treated with ibrutinib and achieved a complete response to therapy after 2 months
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5